Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1381-1400 of 3,900 trials

Atherosclerotic Cardiovascular Disease: Obicetrapib and Ezetimibe Study

We are testing a new combination therapy for people with atherosclerotic cardiovascular disease to see how it affects coronary plaque and overall heart health. This study aims to understand its safety and effectiveness compared to a placebo.

Atherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyEndocrinology

Lung Cancer: Chemoimmunotherapy with MEK Inhibitor

We are testing a new treatment combining chemotherapy and a MEK inhibitor for patients with metastatic non-squamous non-small cell lung adenocarcinoma. The goal is to see if this approach is safe and effective for those with low PD-L1 levels.

Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Oncology

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInfectious DiseasesInternal Medicine

Advanced Epithelial Ovarian Cancer: Radspherin® Treatment

We are studying whether Radspherin® can improve survival and quality of life for patients with advanced ovarian cancer and peritoneal metastasis. This trial focuses on those scheduled for chemotherapy and surgery.

Peritoneal Carcinomatosis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Crohn's Disease: New Ultrasound Method with Microbubbles

We are testing a novel ultrasound technique using oral contrast to improve the detection of Crohn's disease complications. This study aims to see if it can identify issues like ulcers and blockages in the small intestine.

Crohn's Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Alport Syndrome: Dapagliflozin for Kidney Health

We are studying whether Dapagliflozin can help slow the progression of kidney disease in adolescents and young adults with Alport syndrome. This trial aims to improve treatment options for those with this condition.

Alport's Syndrome>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineNephrology

Chondrosarcoma: Ivosidenib Treatment Study

We are studying the effects of ivosidenib in adults with locally advanced or metastatic chondrosarcoma. This trial aims to see if it improves tumor outcomes and overall survival compared to standard treatments.

Chondrosarcoma>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteOncology

Milvexian: Comparing Tablet Formulations for Kids and Adults

We are studying how different tablet forms of milvexian are absorbed in healthy adults and how food affects this process. We also want to know if participants find these formulations acceptable.

Atherothrombotic and Thromboembolic DisordersSafety phase (I)CardiologyInternal Medicine

Chronic Kidney Disease: Camostat Treatment

We are studying the effects of Camostat on kidney function in patients with chronic kidney disease. The goal is to see if it helps with salt and water balance and blood pressure compared to healthy individuals.

Chronic Kidney Disease with Proteinuria1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNephrology

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Seasonal Allergic Rhinitis: PQ Grass Treatment for Kids

We are studying a new treatment for children and teens with seasonal allergic rhinitis caused by grass pollen. The goal is to see if it helps reduce symptoms and is safe for long-term use.

Allergic Rhinitis and Conjunctivitis>2 yearsConfirmation phase (III)>20 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPediatrics

Coronary Artery Disease: Comparing Diabetes Medications

We are studying how well a new diabetes medication works to improve heart health in people with coronary artery disease and prediabetes. This trial compares a GLP-1 agonist and an SGLT-2 inhibitor to standard treatment.

Coronary Artery DiseasePrediabetesCoronary Atherosclerosis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyEndocrinology

PIK3CA-Related Overgrowth Spectrum: Alpelisib Study

We are investigating whether the medication alpelisib is safe and effective for individuals with PIK3CA-related overgrowth spectrum. This study includes both children and adults to assess its impact on their symptoms and overall health.

PIK3CA-Related Overgrowth Spectrum6-12 monthsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Mechanical Heart Valves: Lower INR Study

We are evaluating if a lower INR range is safer and more effective for patients with bileaflet aortic mechanical valves. This may help reduce bleeding risks associated with current treatment methods.

Aortic Valve Replacement Treatment>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Cirrhosis and Portal Hypertension: Metformin Study

We are investigating whether metformin can improve liver blood flow in patients with cirrhosis and portal hypertension. This study will also assess the safety of metformin and its effects on liver health.

Portal Hypertension1-2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHepatologyInternal Medicine

Gabapentin for Nerve Pain in the Leg

We are studying whether gabapentin can reduce leg pain from lower back issues compared to a placebo. The trial also examines its effects on disability, work return, and mental health.

Radicular Leg Pain≤3 monthsConfirmation phase (III)Standard MedicinesNeurologyOrthopedics and Traumatology

Tonsillitis Treatment: Antibiotic vs. No Treatment

We are studying whether an antibiotic can help reduce symptoms in patients with severe tonsillitis who test negative for Streptococcus group A. This trial compares the antibiotic to usual care without antibiotics.

Tonsilitis>2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngology

Chronic Heart Failure: COR-1167 Study

We are testing a new medication, COR-1167, to see how safe it is and how the body processes it in people with chronic heart failure and healthy volunteers. This study aims to gather important information about its effects.

Chronic Heart Failure>2 yearsSafety phase (I)CardiologyInternal Medicine